JLABS @ Washington, DC
Johnson & Johnson Innovation LLC and Children’s National Hospital are collaborating to launch JLABS @ Washington, DC, a 32,000-square foot facility located at the new Children’s National Research & Innovation Campus in Washington, D.C.
The JLABS @ Washington, DC site is open to pharmaceutical, medical device, consumer and health technology companies that are aiming to advance the development of new drugs, medical devices, precision diagnostics and health technologies, including applications in pediatrics.
Johnson & Johnson Innovation seeks to find the best science and technology, no matter where it is located, aiming to solve the greatest unmet medical and healthcare needs of our time. JLABS, in addition to offering emerging life science companies modular lab units, office space, shared core laboratory equipment and business facilities, will link the entrepreneurs within the District and across the greater Virginia and Maryland regions with the full breadth of the Johnson & Johnson Innovation model, including opportunities for funding, third-party services, educational events and R&D experts from medical technology, consumer healthcare product and Janssen pharmaceutical teams.
Applications to join JLABS @ Washington, DC and other JLABS sites are being accepted from biotech, pharmaceutical, medical device, consumer health and health technology companies. Visit the JLABS website to learn more.
BARDA Residency at JLABS @ Washington, DC
As part of the JLABS @ Washington, DC launch, the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, is collaborating with Johnson & Johnson Innovation – JLABS to develop and maintain a specialized innovation zone that is dedicated to the advancement of medical countermeasures aimed at securing our nation from chemical, biological, radiological and nuclear (CBRN) threats, as well as from pandemic influenza and emerging infectious diseases.
The innovation zone provides residency for eligible companies and entrepreneurs focused on solutions with the potential to improve our nation’s response capacity and capabilities to address 21st century health security threats.
QuickFire Challenge to Accelerate Pediatric-Centered Innovation
To mark the launch of the new JLABS on the Children’s National campus and the collaboration with BARDA, JLABS announced the JLABS @ Washington, DC Children’s QuickFire Challenge aiming to accelerate the development and commercialization of pediatric-centered healthcare innovation. Innovators with the best ideas, technologies, or solutions that impact pediatric oncology, pediatric surgical care, and influenza received up to $150,000 in grant funding, residency at JLABS @ Washington, DC with the use of a bench, workstation and access to the JLABS @ Washington, DC community for one year, and mentoring from across the Johnson & Johnson Family of Companies.
Stay informed by signing up for Children’s National Research & Innovation Campus Updates.